Polycythemia vera
Polycythemia vera | |
---|---|
Other names | Polycythaemia vera (PV, PCV), erythremia, primary polycythemia, Vaquez disease, Osler-Vaquez disease, polycythemia rubra vera[1] |
Blood smear from a patient with polycythemia vera | |
Specialty | Oncology, hematology |
In
Most of the health concerns associated with polycythemia vera are caused by the
Signs and symptoms
People with polycythemia vera can be asymptomatic.[4] Clinical symptoms of polycythemia vera are mostly due to hyperviscosity of blood. A classic symptom of polycythemia vera is pruritus or itching, particularly after exposure to warm water (such as when taking a bath),[5] which may be due to abnormal histamine release[6][7] or prostaglandin production.[8] Such itching is present in approximately 40% of patients with polycythemia vera.[9] Gouty arthritis may be present in up to 20% of patients.[9] Peptic ulcer disease is also common in patients with polycythemia vera; most likely due to increased histamine from mast cells, but may be related to an increased susceptibility to infection with the ulcer-causing bacterium H. pylori.[10]
A classic symptom of polycythemia vera (and the related myeloproliferative disease
Pathophysiology
Polycythemia vera (PV), being a primary
Diagnosis
Diagnostic criteria for polycythemia vera were modified by the World Health Organisation in 2016.[16] The WHO criteria for polycythemia vera are specifically outlined in Table 4, and emphasis is given to accurate histological observations as proven predictors in the prognosis of the disease.
As summarized by Verstovek following the 2016 European Hematology Association Congress,[17] there are 3 major criteria for PV diagnosis:
- The first is a very high red blood cell count, which is usually identified by elevated levels of hemoglobin or hematocrit;
- A bone marrow biopsy that shows hypercellularity and abnormalities in megakaryocytes; and
- The presence of a mutation in the Janus kinase 2 (JAK2) gene.
Patients usually have a very low level of erythropoietin, a growth factor that increases the production of red blood cells, which may be considered a minor diagnostic feature.
A mutation in the
People with untreated polycythemia vera have a substantial risk of
Treatment
Untreated, polycythemia vera can be fatal, with the median survival in patients being 1.5-3 years.[26][27][28] Data on the effect of life-span of an individual with treated polycythemia vera is inconclusive due to the rarity of the disease. Studies show the median survival rate of controlled Polycythemia Vera ranges from 10 to 20 years; however, most observations are of people diagnosed in their 60s. Patients live close to a normal life expectancy.[29]
Frequent blood withdrawals (phlebotomy) are one form of treatment, which often may be combined with other therapies. The removal of blood from the body induces iron deficiency, thereby decreasing the hemoglobin / hematocrit level, and reducing the risk of blood clots. Phlebotomy is typically performed to bring their hematocrit (red blood cell percentage) down below 45 for men or 42 for women.[30] It has been observed that phlebotomy also reduces cognitive impairment.[31]
Medications are also used which reduce the number of red blood cells. These include hydroxyurea and interferon therapy, among others.[32] The tendency of some practitioners to avoid chemotherapy if possible, especially in young patients, is a result of research indicating possible increased risk of transformation to acute myelogenous leukemia (AML). While hydroxyurea is considered a safer chemotherapy in this aspect, there is still some debate about its long-term safety.[33]
There are indications that the lung cancer drug erlotinib may be an additional treatment option for those with certain genetic markers.[34]
Ruxolitinib (brand name Jakafi), a Janus kinase 2 (JAK2) inhibitor, is also used to treat polycythemia.[35]
Ropeginterferon alfa-2b (Besremi) was approved for medical use in the European Union in February 2019,[36] and in the United States in November 2021.[37][38] Ropeginterferon alfa-2b is the first medication approved by the U.S. Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera.[37] Interferon alfa-2b is also used.[32]
Epidemiology
Polycythemia vera occurs in all age groups,[39] although the incidence increases with age. One study found the median age at diagnosis to be 60 years,[9] while a Mayo Clinic study in Olmsted County, Minnesota found that the highest incidence was in people aged 70–79 years.[40] The overall incidence in the Minnesota population was 1.9 per 100,000 person-years, and the disease was more common in men than women.[40] A cluster around a toxic site was confirmed in northeast Pennsylvania in 2008.[41]
Notable deaths
- Ron Miles (1963–2022), American jazz trumpeter[43]
- Nell Rankin (1924–2005), American mezzo-soprano[44]
References
- ^ a b "polycythemia vera." at Encyclopædia Britannica. 2010. Encyclopædia Britannica Online. 21 Sep. 2010
- PMID 29296692.
- PMID 35456443. Art. No. 637.
- Mount Sinai Hospital, New York
- S2CID 13638890.
- S2CID 22068469.
- S2CID 38261640.
- S2CID 6909368.
- ^ PMID 1198126.
- PMID 11918555.
- PMID 9263352.
- PMID 9387203.
- PMID 1327286.
- PMID 35315598. Art. No. e87.
- ISBN 978-1-4160-2973-1.
- S2CID 18338178.
- PMID 27930632.
- S2CID 24419497.
- PMID 15837627.
- PMID 27930632.
- PMID 15863514.
- PMID 15858187.
- PMID 19287382.
- PMID 28427458. Art. No. 6.
- S2CID 37383942.
- ^ Mayo Clinic staff. "Polycythemia vera - MayoClinic.com". Polycythemia vera: Definition. Mayo Clinic. Retrieved 2011-09-03.
- ^ "What Is Polycythemia Vera?". National Heart, Lung and Blood Institute. Retrieved 2011-09-03.
- ^ "Polycythemia Vera Follow-up". Retrieved 2011-09-03.
- PMID 27930632.
- PMID 11830459.
- S2CID 40928145.
- ^ a b "Polycythemia vera - Diagnosis and treatment - Mayo Clinic". www.mayoclinic.org. Retrieved 2022-03-11.
- PMID 21537037.
- PMID 17178722.
- PMID 29321547.
- ^ "Besremi EPAR". European Medicines Agency (EMA). 12 December 2018. Retrieved 14 November 2021.
- ^ a b "FDA Approves Treatment for Rare Blood Disease". U.S. Food and Drug Administration (FDA) (Press release). 12 November 2021. Retrieved 12 November 2021. This article incorporates text from this source, which is in the public domain.
- ^ "U.S. FDA Approves Besremi (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera" (Press release). PharmaEssentia. 12 November 2021. Retrieved 14 November 2021 – via Business Wire.
- PMID 12551821.
- ^ S2CID 31536624.
- ^ MICHAEL RUBINKAM (2008). "Cancer cluster confirmed in northeast Pennsylvania". Associated Press. Archived from the original on September 2, 2008.
- The Courier-Journal. Retrieved May 16, 2020.
- ^ Harrington, Jim (March 9, 2022). "'Gifted artist' Ron Miles dies of a rare blood disorder at 58". The Mercury News. Retrieved March 10, 2022.
- ^ Allan Kozinn (January 19, 2005). "Nell Rankin Is Dead at 81; Mezzo-Soprano With Met". The New York Times.
External links
- Polycythemia Vera National Heart, Lung, and Blood Institute
- 11-141d. at Merck Manual of Diagnosis and Therapy Professional Edition